Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Sara Michell Tolaney, M.D.

Title
Institution
Department
Address
Phone

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
Displaying 25 of 360 total Publications Show all
  1. Lynce F, Martínez-Sáez O, Walbaum B, Brasó-Maristany F, Waks AG, Villagrasa P, Villacampa Javierre G, Sanfeliu E, Galván P, Paré L, Anderson LM, Perou CM, Parker JS, Vivancos A, DiLullo MK, Pernas S, Winer EP, Overmoyer B, Mittendorf EA, Bueno-Muiño C, Martín M, Prat A, Tolaney SM. HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers. ESMO Open. 2025 Jan 17; 10(2):104100. PMID: 39826476.
    Citations: Article has an altmetric score of 12
  2. Qiu X, Tarantino P, Li R, Grinshpun A, Gupta H, Hughes ME, Kirkner G, Scholl L, Johnson BE, Meyerson M, Cherniack AD, Jiang Y, Zhou N, Lin NU, Long HW, Tolaney SM, Jeselsohn R. Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2. ESMO Open. 2025 Jan 17; 10(2):104111. PMID: 39826477.
    Citations: Article has an altmetric score of 5
  3. Pereslete AM, Hughes ME, Martin AR, Files J, Nguyen K, Buckley L, Patel A, Moore A, Winer EP, Dillon D, Li T, Tolaney SM, Lin NU, Sammons SL. Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival. Neuro Oncol. 2025 Jan 12; 27(1):184-194. PMID: 39211994; PMCID: PMC11726339.
    Citations: 2 Article has an altmetric score of 18
    Fields: NeoNeoplasmsNeuNeurology
  4. Hart LL, Im SA, Tolaney SM, Campone M, Pluard T, Sousa B, Freyer G, Decker T, Kalinsky K, Sopher G, Gao M, Hu H, Kuemmel S. Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials. Eur J Cancer. 2025 Jan 08; 217:115225. PMID: 39826197.
    Citations: Article has an altmetric score of 3
    Fields: NeoNeoplasms
  5. O'Meara TA, Tarantino P, Morganti S, Schlam I, Garrido-Castro AC, Tolaney SM. Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing. Curr Oncol Rep. 2025 Jan; 27(1):68-79. PMID: 39786525.
    Citations: Article has an altmetric score of 16
    Fields: NeoNeoplasms
  6. Lamont EB, Stein E, Tarantino P, Tolaney SM, Ahlberg C, Chinnathambu K, Qi J, Bilan J, Davi R, Ensign L. Pooled clinical trial analyses evaluating outcomes of HER2-low vs HER2-0 expression in patients with metastatic breast cancer following chemotherapy. Breast Cancer Res Treat. 2025 Feb; 210(1):11-14. PMID: 39707103.
    Citations: Article has an altmetric score of 8
    Fields: NeoNeoplasms
  7. Schlam I, Hirko KA, Shveid D, Abuali I, Sewaralthahab S, Nakhils F, Hazra A, Lengyel C, Altuna S, Hussain S, Seid F, Jamil S, Odhiambo A, Leone JP, Metzger O, Abraham J, Soto-Perez-de-Celis E, Chen WY, Block C, Schumer S, Bellon JR, Valenza C, Curigliano G, Tolaney SM, Lynce F, Trapani D. Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES Study. JCO Glob Oncol. 2024 Dec; 10:e2400307. PMID: 39705637.
    Citations: Article has an altmetric score of 9
    Fields: NeoNeoplasmsTranslation:Humans
  8. Schettini F, Nucera S, Pascual T, Martínez-Sáez O, Sánchez-Bayona R, Conte B, Buono G, Lambertini M, Punie K, Cejalvo JM, Arpino G, Vigneri P, Generali D, Ciruelos E, Cortés J, Gennari A, Muñoz M, Vidal Losada MJ, Tolaney SM, Prat A, Villacampa G. Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis. Cancer Treat Rev. 2025 Jan; 132:102865. PMID: 39709655.
    Citations: Article has an altmetric score of 5
    Fields: AntAntineoplastic AgentsNeoNeoplasmsTranslation:Humans
  9. Fanucci K, Giordano A, Erick T, Tolaney SM, Sammons S. Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) advanced breast cancer. ESMO Open. 2024 Dec; 9(12):103997. PMID: 39674130; PMCID: PMC11699375.
    Citations: Article has an altmetric score of 22
    Translation:HumansCells
  10. Leone JP, Leone J, Hassett MJ, Freedman RA, Avila J, Vallejo CT, Tayob N, Tolaney SM, Lin NU. Incidence, treatment patterns, and mortality for patients with breast cancer during the first year of the COVID-19 pandemic: a population-based study. Breast Cancer Res Treat. 2024 Dec 02. PMID: 39621161.
    Citations: Article has an altmetric score of 5
    Fields: NeoNeoplasms
  11. Shimada K, Michaud DE, Cui YX, Zheng K, Goldberg J, Ju Z, Schnitt SJ, Pastorello R, Kania LD, Hoffer J, Muhlich JL, Hyun N, Krueger R, Gottlieb A, Nelson A, Wanderley CW, Antonellis G, McAllister SS, Tolaney SM, Waks AG, Jeselsohn R, Sorger PK, Agudo J, Mittendorf EA, Guerriero JL. An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancer. bioRxiv. 2024 Nov 25. PMID: 39651157; PMCID: PMC11623498.
    Citations: Article has an altmetric score of 1
  12. Tolaney SM, Tung N, Wolff AC, DeMichele A, Cejalvo JM, Martínez-Sáez O, Pascual T, Waks AG, Martín M, Ciruelos E, Harbeck N, Carey LA, Cortés J, Curigliano G, Prat A. HER2DX genomic test in early-stage HER2-positive breast cancer. ESMO Open. 2024 Dec; 9(12):103987. PMID: 39710442; PMCID: PMC11614791.
    Citations: Article has an altmetric score of 7
    Translation:Humans
  13. Corti C, Binboga Kurt B, Koca B, Rahman T, Conforti F, Pala L, Bianchini G, Criscitiello C, Curigliano G, Garrido-Castro AC, Kabraji SK, Waks AG, Mittendorf EA, Tolaney SM. Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy. Cancer Treat Rev. 2025 Jan; 132:102852. PMID: 39571402.
    Citations: 1 Article has an altmetric score of 41
    Fields: AntAntineoplastic AgentsNeoNeoplasmsTranslation:HumansCells
  14. Pan S, Gadrey JY, Sammons S, Lin NU, Tolaney SM, Tarantino P, Schlam I. Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases. Ther Adv Med Oncol. 2024; 16:17588359241292266. PMID: 39529890; PMCID: PMC11552056.
    Citations: Article has an altmetric score of 48
  15. Nader-Marta G, Waks AG, Tolaney SM, Mayer EL. Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer. ESMO Open. 2024 Nov; 9(11):103977. PMID: 39510023; PMCID: PMC11575057.
    Citations: Article has an altmetric score of 13
  16. Raghavendra AS, Zakon DB, Jin Q, Strahan A, Grimm M, Hughes ME, Cherian M, Vincuilla J, Parker T, Tarantino P, Mittendorf EA, King TA, Valero V, Tripathy D, Tolaney SM, Tayob N, Lin NU, Stover DG, Barcenas CH, Garrido-Castro AC. Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status?. ESMO Open. 2024 Nov; 9(11):103973. PMID: 39500139; PMCID: PMC11570474.
    Citations: Article has an altmetric score of 23
    Translation:Humans
  17. Tarantino P, Hortobagyi G, Tolaney SM, Mittendorf EA. Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review. JAMA Oncol. 2024 Nov 01; 10(11):1578-1584. PMID: 39264638.
    Citations: Article has an altmetric score of 77
    Fields: NeoNeoplasmsTranslation:Humans
  18. Giordano A, Kumthekar PU, Jin Q, Binboga Kurt B, Ren S, Li T, Leone JP, Mittendorf EA, Pereslete AM, Sharp L, Davis R, DiLullo M, Tayob N, Mayer EL, Winer EP, Tolaney SM, Lin NU. A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2024 Nov 01; 30(21):4856-4865. PMID: 39226397; PMCID: PMC11528201.
    Citations: Article has an altmetric score of 12
    Fields: NeoNeoplasmsTranslation:HumansCTClinical Trials
  19. Klughammer J, Abravanel DL, Segerstolpe Å, Blosser TR, Goltsev Y, Cui Y, Goodwin DR, Sinha A, Ashenberg O, Slyper M, Vigneau S, Jané-Valbuena J, Alon S, Caraccio C, Chen J, Cohen O, Cullen N, DelloStritto LK, Dionne D, Files J, Frangieh A, Helvie K, Hughes ME, Inga S, Kanodia A, Lako A, MacKichan C, Mages S, Moriel N, Murray E, Napolitano S, Nguyen K, Nitzan M, Ortiz R, Patel M, Pfaff KL, Porter CBM, Rotem A, Strauss S, Strasser R, Thorner AR, Turner M, Wakiro I, Waldman J, Wu J, Gómez Tejeda Zañudo J, Zhang D, Lin NU, Tolaney SM, Winer EP, Boyden ES, Chen F, Nolan GP, Rodig SJ, Zhuang X, Rozenblatt-Rosen O, Johnson BE, Regev A, Wagle N. A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features. Nat Med. 2024 Nov; 30(11):3236-3249. PMID: 39478111; PMCID: PMC11564109.
    Citations: Article has an altmetric score of 149
    Fields: MedMedicine (General)MolMolecular BiologyTranslation:HumansCells
  20. Valenza C, Trapani D, Zagami P, Antonarelli G, Boscolo Bielo L, Nicolò E, Ribeiro JM, Guidi L, Reduzzi C, Spotti M, Adamoli L, Cortès J, Pistilli B, Tolaney SM, Ueno N, Layman RM, Cristofanilli M, Carey LA, Munzone E, Criscitiello C, Lynce F, Woodward WA, Curigliano G. Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study. Eur J Cancer. 2024 Dec; 213:115097. PMID: 39486164.
    Citations: Article has an altmetric score of 9
    Fields: NeoNeoplasmsTranslation:Humans
  21. Jovanovic B, Church SE, Gorman KM, North K, Richardson ET, DiLullo M, Attaya V, Kasparian J, Mohammed-Abreu A, Kirkner G, Hughes ME, Lin NU, Mittendorf EA, Schnitt SJ, Tolaney SM, Goel S. Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies. Clin Cancer Res. 2024 Oct 15; 30(20):4768-4779. PMID: 39136550; PMCID: PMC11474168.
    Citations: Article has an altmetric score of 12
    Fields: NeoNeoplasmsTranslation:HumansCells
  22. Tarantino P, Tolaney SM. Progress in breast cancer management. Lancet. 2024 Oct 12; 404(10461):1376-1378. PMID: 39396338.
    Citations: Article has an altmetric score of 12
    Fields: MedMedicine (General)Translation:Humans
  23. Schade AE, Perurena N, Yang Y, Rodriguez CL, Krishnan A, Gardner A, Loi P, Xu Y, Nguyen VTM, Mastellone GM, Pilla NF, Watanabe M, Ota K, Davis RA, Mattioli K, Xiang D, Zoeller JJ, Lin JR, Morganti S, Garrido-Castro AC, Tolaney SM, Li Z, Barbie DA, Sorger PK, Helin K, Santagata S, Knott SRV, Cichowski K. AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Nature. 2024 Nov; 635(8039):755-763. PMID: 39385030; PMCID: PMC11578877.
    Citations: Article has an altmetric score of 117
    Fields: SciScienceTranslation:HumansAnimalsCells
  24. Villanova M, Tolaney SM, Min L. Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients. Endocr Relat Cancer. 2024 Nov 01; 31(11). PMID: 39235349.
    Citations: Article has an altmetric score of 9
    Fields: EndEndocrinologyNeoNeoplasmsTranslation:Humans
  25. Mittendorf EA, Tolaney SM. Neoadjuvant Immunotherapy-From Trials to Practice. JAMA Oncol. 2024 Oct 01; 10(10):1319-1321. PMID: 39207783.
    Citations: 1 Article has an altmetric score of 57
    Fields: NeoNeoplasms
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contact@catalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resources@hms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappt@hms.harvard.edu.
Tolaney's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (456)
Explore
_
Co-Authors (242)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
© 2025 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.